What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Alzheimer's disease
His primary scientific interests are in Alzheimer's disease, Internal medicine, Pathology, Cerebrospinal fluid and Dementia.
His study focuses on the intersection of Alzheimer's disease and fields such as Central nervous system disease with connections in the field of Cognitive disorder.
In his research, Cohort study is intimately related to Oncology, which falls under the overarching field of Internal medicine.
His Cerebrospinal fluid research includes elements of Csf biomarkers, Immunology, Disease, Amyloid and Traumatic brain injury.
His research in Dementia intersects with topics in Cognition, Neurology and Neuroimaging.
The study incorporates disciplines such as Immunoassay, Neuropathology and Neurodegeneration in addition to Biomarker.
His most cited work include:
- Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. (3383 citations)
- NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease (2145 citations)
- Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria (1750 citations)
What are the main themes of his work throughout his whole career to date?
Kaj Blennow mainly investigates Internal medicine, Cerebrospinal fluid, Disease, Pathology and Biomarker.
His work deals with themes such as Endocrinology, Neurology and Oncology, which intersect with Internal medicine.
Kaj Blennow has included themes like Gastroenterology, Neurodegeneration, Immunology and Amyloid in his Cerebrospinal fluid study.
The various areas that Kaj Blennow examines in his Disease study include Neuroimaging, Neuroscience and Clinical trial, Bioinformatics.
His Dementia research is multidisciplinary, incorporating elements of Cognition and Cohort.
The concepts of his Alzheimer's disease study are interwoven with issues in Apolipoprotein E and Central nervous system disease, Degenerative disease.
He most often published in these fields:
- Internal medicine (61.40%)
- Cerebrospinal fluid (58.14%)
- Disease (42.31%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (61.40%)
- Cerebrospinal fluid (58.14%)
- Disease (42.31%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Cerebrospinal fluid, Disease, Biomarker and Dementia.
He works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Neuroimaging.
His Cerebrospinal fluid study is concerned with the larger field of Pathology.
His biological study spans a wide range of topics, including Clinical trial, Bioinformatics and Cognition, Neuroscience.
His Biomarker research is multidisciplinary, relying on both Positron emission tomography, Prospective cohort study, Area under the curve and Glial fibrillary acidic protein.
His Dementia study integrates concerns from other disciplines, such as Alzheimer's disease, Apolipoprotein E and Cohort.
Between 2019 and 2021, his most popular works were:
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia (135 citations)
- Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia (135 citations)
- Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. (123 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
